Covestor’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16K Buy
29
+4
+16% +$2.07K 0.01% 1215
2026
Q2
$14K Sell
25
-30
-55% -$16.9K 0.01% 1349
2026
Q1
$33K Sell
55
-81
-60% -$40.3K 0.02% 925
2025
Q4
$67K Sell
136
-233
-63% -$109K 0.04% 788
2025
Q3
$155K Sell
369
-30
-8% -$10.1K 0.09% 323
2025
Q2
$115K Sell
399
-191
-32% -$57.1K 0.07% 469
2025
Q1
$182K Sell
590
-16
-3% -$5.48K 0.12% 187
2024
Q4
$214K Buy
606
+317
+110% +$117K 0.13% 153
2024
Q3
$103K Sell
289
-176
-38% -$59.5K 0.06% 497
2024
Q2
$148K Sell
465
-44
-9% -$11.6K 0.1% 283
2024
Q1
$117K Buy
509
+231
+83% +$52.1K 0.07% 435
2023
Q4
$61K Sell
278
-534
-66% -$123K 0.04% 760
2023
Q3
$183K Sell
812
-362
-31% -$83.4K 0.14% 140
2023
Q2
$259K Buy
1,174
+267
+29% +$59.1K 0.2% 60
2023
Q1
$203K Buy
907
+15
+2% +$3.7K 0.18% 104
2022
Q4
$248K Sell
892
-17
-2% -$4.29K 0.2% 67
2022
Q3
$190K Sell
909
-8
-0.9% -$1.79K 0.17% 92
2022
Q2
$216K Buy
917
+40
+5% +$8.13K 0.17% 98
2022
Q1
$157K Buy
877
+572
+188% +$109K 0.1% 254
2021
Q4
$66K Buy
+305
New +$59.9K 0.09% 374

Other funds holding UTHR

Covestor's UTHR Position: Q3 2026 in Review

Covestor increased its United Therapeutics (UTHR) stake by 16% in Q3 2026, buying an estimated $2.07K and bringing the position to 29 shares worth $16K. The position accounts for 0.01% of the portfolio, ranked #1215.

Covestor first reported a position in UTHR in Q4 2021 and has held it in 20 quarters since. The position peaked at $259K in Q2 2023. 477 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Covestor held 29 shares of United Therapeutics worth $16K as of Q3 2026.
  • Covestor bought 4 United Therapeutics shares in Q3 2026, an estimated $2.07K.
  • United Therapeutics made up 0.01% of Covestor's portfolio in Q3 2026, its #1215 holding.
  • Covestor first reported a position in United Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • Covestor's United Therapeutics position peaked at $259K in Q2 2023.
  • 477 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.